BWAY Stock Analysis: Buy, Sell, or Hold?
BWAY - Brainsway Ltd. American Depositary Shares
$14.74
-0.23 (-1.54%)
▼
5d:
-9.68%
30d:
-10.72%
90d:
-2.25%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When BWAY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BWAY shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BWAY shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$23.69
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$14.71
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BWAY is currently trading at $14.74, which is considered oversold relative to its 30-day fair value range of $14.85 to $16.19. From a valuation perspective, the stock is trading at a discount (Forward PE: 30.3) compared to its historical average (47.1). Remarkably, the market is currently pricing in an annual earnings decline of 13.7% over the next few years. This pessimistic expectation contrasts with the company's recent 64.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BWAY is showing sideways momentum. The price is currently testing key support at $14.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $18.60 (+26.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BWAY is showing sideways momentum. The price is currently testing key support at $14.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $18.60 (+26.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$14.85 -
$16.19
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (56/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 26.2% below Wall St target ($18.60)
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$14.85 -
$16.19
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$14.52
Resistance Level
$17.40
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
30.29
Wall Street Target
$18.60
(+26.2%)
Revenue Growth (YoY)
35.4%
Earnings Growth (YoY)
64.6%
Profit Margin
15.6%
Valuation Discount vs History
-13.7% cheaper
PE vs Historical
30.3 vs 47.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-13.7%
(market-implied from PE analysis)
1-Year Target
$13.27
(-10%)
2-Year Target
$11.94
(-19%)
3-Year Target
$10.75
(-27%)
3-Yr Target (if PE normalizes)
(PE: 30→47)
$16.71
(+13%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 30.3, Growth: 80.3%)
$49.75
(+238%)
Base:
(SPY PE: 20.1, Growth: 80.3%)
$32.97
(+124%)
Bear:
(PE: 17.1, Growth: 80.3%)
$28.02
(+90%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (36x PE), but valuation improves significantly next year (30x PE) as earnings recover.
Forward PE: 36.10 | Forward EPS (Implied): $0.41
Bull Case
$17.80
(+21%)
Analyst growth 15.0%, PE expands to 37.9
Base Case
$14.74
(0%)
Market implied 0.0%, PE stable at 36.1
Bear Case
$11.28
(-24%)
Severe decline -15.0%, PE contracts to 32.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 30.3 to 47.1
Stabilization Target:
$22.92
(+55.5%)
PE Expansion Potential:
+55.5%
Share & Embed Analysis
Last updated: August 22, 2026 6:41 PM ET
Data refreshes hourly during market hours. Next update: 7:41 PM
Data refreshes hourly during market hours. Next update: 7:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BWAY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$119 | 37 SELL |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 35 SELL |
